Comparison · NCT02684253-sae
Nivolumab 3mg/kg IV Every 2 Weeks vs Stereotactic Body Radiotherapy & Nivolumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nivolumab 3mg/kg IV Every 2 Weeks vs Stereotactic Body Radiotherapy & Nivolumab: serious adverse events. Trial comparisons, record NCT02684253-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02684253-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.125 | 0.0497 | 0.281 | wilson | |
| Risk in group 2 | 0.0909 | 0.0314 | 0.236 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0341 | -0.129 | 0.201 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.38 | 0.334 | 5.66 | log | |
| Odds ratio, group 1 over group 2 | 1.43 | 0.293 | 6.96 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Nivolumab 3mg/kg IV Every 2 Weeks than on Stereotactic Body Radiotherapy & Nivolumab | 29.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nivolumab 3mg/kg IV Every 2 Weeks | Nivolumab 3mg/kg IV every 2 weeks~Nivolumab | 4 | 32 | EG000 |
| Group 2 | Stereotactic Body Radiotherapy & Nivolumab | Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab).~Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity.~Nivolumab~Stereotactic Body Radiation Therapy (SBRT) | 3 | 33 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up tp 30 months
Source ClinicalTrials.gov
Trial
- Title
- Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- NCT number
- NCT02684253
- Phases
- PHASE2
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Nivolumab, Stereotactic Body Radiation Therapy (SBRT)
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Results first posted
- 2022-03-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02684253?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02684253-sae